by
Hanoğlu, Berçem Dilan, author.
Format:
El Yazması
Alıntı:
Increasing doxorubicin (Dox) release from liposomes / Hanoğlu, Berçem Dilan, author.
by
Demir, Ayşe Banu, author.
Format:
El Yazması
Alıntı:
Indentification of doxorubicin drug resistance mechanisms by using genomic techniques/ Demir, Ayşe
by
Özkıyıcı, Selin, author.
Format:
El Yazması
Alıntı:
Development of endosome disruptive peptide and PEG conjugate based doxorubicin delivery system /
by
Zeybek, Ayça.
Format:
El Yazması
Alıntı:
The effect of doxorubicin-albumin magnetic nanoparticles on prostate and lung cancer cells/ Zeybek
by
Önol, Ayşenur Başar, author.
Format:
El Yazması
Alıntı:
Development of doxorubicin loaded liposomes self-assembled with polysaccharides for breast cancer
by
Coşkun, Sema, author.
Format:
El Yazması
Alıntı:
Doxorubicin.
by
Önercan, Cansu, author.
Format:
El Yazması
Alıntı:
Doxorubicin.
by
Gökçe, Begüm, author.
Format:
El Yazması
Alıntı:
Doxorubicin.
by
Mete, Derya, author.
Format:
El Yazması
Alıntı:
cancerous cells are more acidic than healthy cells, our studies aim to ensure that doxorubicin, sorafenib
by
Alkan, Ayşe Hale, author.
Format:
El Yazması
Alıntı:
investigated. Candidate lncRNAs from Doxorubicin, Fas mAB, TNF-alpha and Cisplatin treated HeLa cell line were
by
Yaylak, Bilge, author.
Format:
El Yazması
Alıntı:
/or global circRNAs in apoptotic HeLa cells. Cisplatin (CP), doxorubicin (DOX), Fas mAb(FAS) and
by
Kankale, Deniz, author.
Format:
El Yazması
Alıntı:
widely used anticancer drug. Here, doxorubicin uptake by highly metastatic human breast cancer cell line
Page
of 2